Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Trial of Pembrolizumab in Combination With Blinatumomab in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

NCT03512405 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03512405
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03512405 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Trial of Pembrolizumab in Combination With Blinatumomab in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Lead sponsor
City of Hope Medical Center
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 2, 2019
Completion date
November 11, 2025
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cd19 positive, philadelphia chromosome positive, recurrent acute lymphoblastic leukemia, refractory acute lymphoblastic leukemia